-
3821por Fernández, Ariel“…This therapeutic modality would not a-priori interfere directly with current efforts toward the immunological targeting of the RBD epitope; hence, it could be exploited as a complementary treatment.…”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3822por Byeon, Haewon“…The results of this study imply that this approach could be useful for measuring the severity of dementia by comprehensively examining axial atypical features, the Korean instrumental activities of daily living (K-IADL), changes in rapid eye movement sleep behavior disorder (RBD), etc. for optimal intervention and caring of the elderly living alone or patients with PDD residing in medically vulnerable areas.…”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3823por Bates, Timothy A., Leier, Hans C., Lyski, Zoe L., McBride, Savannah K., Coulter, Felicity J., Weinstein, Jules B., Goodman, James R., Lu, Zhengchun, Siegel, Sarah A. R., Sullivan, Peter, Strnad, Matt, Brunton, Amanda E., Lee, David X., Curlin, Marcel E., Messer, William B., Tafesse, Fikadu G.“…Age is negatively correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies are proportional to neutralizing activities.…”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3824“…Recombinant human ACE2 (rhACE2) functionalized onto the surface of cytomimetic particles binds the receptor binding domain (RBD) of recombinant SARS-CoV-2 spike protein with high affinity and demonstrated a stoichiometric advantage over the use of soluble rhACE2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3825por Su, Zhiying, Hu, Wenjia, Liu, Qianyun, Zhang, Yongxi, Chen, Tielong, Zhou, Yingying, Zhang, Zhen, Chen, Yu, Yang, Rongrong, Xiong, Yong, Wang, Xinghuan“…In this study, through CoV-psV neutralization assay and IFN-γ ELISpot testing in 30 cases of COVID-19 patients after 9 months post-SARS-CoV-2 infection, it found that the ratio of memory/naive CD4(+) T lymphocytes cells and levels of anti-SARS-CoV-2-IgM and RBD-IgM were slightly but significantly higher in COVID-19 severe convalescent patients than that in non-severe patients. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3826“…The measured binding interactions for RBD and NCP proteins with their corresponding antibodies under different conditions have been measured and analyzed. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3827“…The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3828por Abdelmohsen, Usama Ramadan, Albohy, Amgad, Abdulrazik, Basma S., Bayoumi, Soad A. L., Malak, Lourin G., Khallaf, Iman S. A., Bringmann, Gerhard, Farag, Salwa F.“…Using virtual-screening methods, the selected compounds were investigated for potential inhibition of viral main protease (Mpro), viral methyltransferase (nsp16/10 complex), viral recognition binding domain (RBD) of S-protein, and human angiotensin-converting enzyme 2 (ACE2), which is the human receptor for viral S-protein targets, using molecular-docking studies. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3829“…Deep mutational scanning (DMS) experiments have been performed on SARS-CoV-2’s spike receptor-binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2) zinc-binding peptidase domain—both central players in viral infection and evolution and antibody evasion—quantifying how mutations impact biochemical phenotypes. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3830“…We show that the Ig-VAE can be used with Rosetta to create a computational model of a SARS-CoV2-RBD binder via latent space sampling. We further demonstrate that the model’s generative prior is a powerful tool for guiding computational protein design, motivating a new paradigm under which backbone design is solved as constrained optimization problem in the latent space of a generative model.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3831por Compagnone, Mirco, Pinto, Eleonora, Salvatori, Erika, Lione, Lucia, Conforti, Antonella, Marchese, Silvia, Ravà, Micol, Ryan, Kathryn, Hall, Yper, Rayner, Emma, Salguero, Francisco J., Paterson, Jemma, Iannacone, Matteo, De Francesco, Raffaele, Aurisicchio, Luigi, Palombo, Fabio“…To further explore alternative vaccination platforms, we developed COVID-eVax—a genetic vaccine based on plasmid DNA encoding the RBD domain of the SARS-CoV-2 spike protein. Here, we describe the correlation between immune responses and the evolution of viral infection in ferrets infected with the live virus. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3832“…In this study, we accomplish our work with the mutations in receptor binding domain (RBD) of Spike (S) protein considering different aspects like the hACE-2 variants in human populations to get an idea about the varying infectivity of different strains for different population. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3833por Seow, Jeffrey, Khan, Hataf, Rosa, Annachiara, Calvaresi, Valeria, Graham, Carl, Pickering, Suzanne, Pye, Valerie E., Cronin, Nora B., Huettner, Isabella, Malim, Michael H., Politis, Argyris, Cherepanov, Peter, Doores, Katie J.“…While extensive research has shown that the receptor binding domain (RBD) and, to a lesser extent, the N-terminal domain (NTD) are the predominant targets for neutralizing antibodies, identification of neutralizing epitopes beyond these regions is important for informing vaccine development and understanding antibody-mediated immune escape. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3834por Hillus, David, Schwarz, Tatjana, Tober-Lau, Pinkus, Vanshylla, Kanika, Hastor, Hana, Thibeault, Charlotte, Jentzsch, Stefanie, Helbig, Elisa T, Lippert, Lena J, Tscheak, Patricia, Schmidt, Marie Luisa, Riege, Johanna, Solarek, André, von Kalle, Christof, Dang-Heine, Chantip, Gruell, Henning, Kopankiewicz, Piotr, Suttorp, Norbert, Drosten, Christian, Bias, Harald, Seybold, Joachim, Klein, Florian, Kurth, Florian, Corman, Victor Max, Sander, Leif Erik“…Immunogenicity was measured by the presence of SARS-CoV-2-specific antibodies (full spike-IgG, S1-IgG, and RBD-IgG), by an RBD–ACE2 binding inhibition assay (surrogate SARS-CoV-2 virus neutralisation test), a pseudovirus neutralisation assay against two variants of concerns (alpha [B.1.1.7] and beta [B.1.351]), and anti-S1-IgG avidity. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3835por Dahiya, Saurabh, Luetkens, Tim, Avila, Stephanie, Dahiya, Saurabh, Margiotta, Philip, Hankey, Kim, Lesho, Patricia, Bauman, Sherri, Smith, Nancy, Ruehle, Kathleen, Lee, Seung-Tae, Law, Jennie Y., Baddley, John, Kocoglu, Mehmet Hakan, Yared, Jean A., Hardy, Nancy M., Rapoport, Aaron P., Atanackovic, Djordje“…The vast majority of our CAR-T patients did not evidence IgG antibody responses against any of the SARS-CoV-2 proteins analyzed such as S1, S1 delta, RBD, RBD delta, or S2 (Figure 2B). Conclusion: In this prospectively conducted clinical study, 18 of 19 patients with lymphoma who have received CD19 CAR-T therapy had poor immunogenicity against mRNA based COVID-19 vaccines as measured by neutralization assays and antibody titers. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3836por Szabó, Enikő, Modok, Szabolcs, Rónaszéki, Benedek, Faragó, Anna, Gémes, Nikolett, Nagy, Lajos I., Hackler, László, Farkas, Katalin, Neuperger, Patrícia, Balog, József Á., Balog, Attila, Puskás, László G., Szebeni, Gabor J.“…Cases that underwent the anti-CD20 therapy resulted in significantly weaker ((**)p < 0.01) anti-RBD IgG level (302 BAU/mL) than without CD20 blocking in the HD group (928 BAU/mL). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3837por Huang, Bin, Cai, Yun, Li, Ning, Li, Kening, Wang, Zhihua, Li, Lu, Wu, Lingxiang, Zhu, Mengyan, Li, Jie, Wang, Ziyu, Wu, Min, Li, Wanlin, Wu, Wei, Zhang, Lishen, Xia, Xinyi, Wang, Shukui, Chen, Hongshan, Wang, Qianghu“…The total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels were measured by chemiluminescence. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3838por Spinelli, Matthew A, Peluso, Michael J, Lynch, Kara, Yun, Cassandra, Glidden, David V, Henrich, Timothy J, Deeks, Steve, Gandhi, Monica“…We defined a non-response as reciprocal pseudovirus neutralizing titer< 10 and anti-RBD IgG< 10 relative fluorescent units, and compared non-response by HIV status using mixed models. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3839por Dyer, Adam H., Noonan, Claire, McElheron, Matt, Batten, Isabella, Reddy, Conor, Connolly, Emma, Pierpoint, Rachel, Murray, Caroline, Leonard, Ann, Higgins, Catriona, Reilly, Phyllis, Boran, Gerard, Phelan, Thomas, McCormack, William, O'Neill, Desmond, Fallon, Aoife, Brady, Gareth, O'Farrelly, Cliona, Bourke, Nollaig M., Kennelly, Sean P.“…Serum nucleocapsid and anti-spike receptor binding domain (RBD) antibodies were analyzed at all timepoints. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3840por Diamantopoulos, Panagiotis T., Stafylidis, Christos, Vlachopoulou, Dimitra, Kontandreopoulou, Christina-Nefeli, Giannakopoulou, Nefeli, Vardaka, Maria, Mpouhla, Anthi, Mastrogianni, Elpida, Variami, Eleni, Galanopoulos, Athanasios, Pappa, Vasiliki, Psichogiou, Mina, Hatzakis, Angelos, Viniou, Nora-Athina“…Sera were tested before the first and after the second dose of the vaccine for anti-SARS-CoV-2 receptor binding domain (RBD) spike protein IgG (anti-RBD), using the Abbott SARS-CoV-2 IgG II Quant assay (Abbott Laboratories, Abbott Park, IL, USA), with a cutoff value for seroconversion at 50 AU/ml. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto